Yesterday was the sec­ond day of the 2012 American Society of He­ma­tol­ogy (ASH) annual meeting, which is being held in Atlanta.

The day's myeloma-related pre­sen­ta­tions began in the afternoon with three sessions of oral pre­sen­ta­tions.  Two of the sessions focused on re­­sults from clin­i­cal trials, most of which studied drugs that are still being devel­oped for the treat­ment of mul­ti­ple myeloma.  The third session, which focused on the biology of myeloma, ran simultaneously with one of the sessions about clin­i­cal trial re­­sults.

An up­date pub­lished yes­ter­day evening summarized the re­­sults for the …

This year’s American Society of Hematology (ASH) annual meeting, which is being held in Atlanta, began yesterday and goes through Tuesday.

Today’s myeloma-related presentations began this afternoon with three sessions of oral presentations.  Two of the sessions focused on results from clin­i­cal trials, most of which studied drugs that are still under devel­op­ment as poten­tial treat­ments for multiple myeloma.  The third session, which focused on the biology of myeloma, ran simultaneously with one of the sessions about clin­i­cal trial results.

This article will summarize the first oral session about multiple myeloma treat­ments, …

Yesterday was the first day of research presentations at this year’s American Society of Hematology (ASH) annual meeting, which is being held in Atlanta.

Research findings related to multiple myeloma was presented in three different sessions during the day.

Two of the sessions were actually the same general educational session about multiple myeloma, repeated at two different times during the day. The Beacon will cover the presentations given during those sessions in a separate daily update.

The key myeloma-related research presented yesterday, however, was made public during a poster session in the …